The US regulator says Retevmo (selpercatinib, formerly LOXO-292) can be used to treat lung and thyroid cancers with a mutation or fusion in the RET gene, specifically non-small cell lung cancer ...

NTRK fusion cancer is rare, affecting no more than a ... and is more common in sarcomas, brain, kidney and thyroid cancers. Use of the drug will depend on patients receiving genetic testing ...

NTRK fusion genes occur in various types of adult and pediatric tumors. In some rare tumors, such as salivary gland carcinoma, secretory breast cancer, and infantile fibrosarcoma, the incidence of ...

British Journal of Cancer, part of leading science journal Nature, published a paper entitled "Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK ...

for advanced solid tumours harbouring neurotrophic tyrosine receptor kinase (NTRK) fusion genes. Previously, the CDE had accepted the new drug application (NDA) for the pan-tropomyosin receptor ...

Removing Ovaries and Fallopian Tubes Linked to Lower Risk of Early Death Among Breast Cancer Patients With BRCA Cancer Genes May 7, 2025 — Women diagnosed with breast cancer who carry particular ...

With your ruler, the moon, moving into an uncomfortable angle with the Sun today, you need to be choosy about the company you keep. In a perfect world, you could sneak off to a quiet sanctuary to ...

Researchers from MIT and Dana-Farber Cancer Institute have discovered that a class of peptides expressed in pancreatic cancer cells could be a promising target for T-cell therapies and other ...